Physician profile
Sunil Mathews
NPI 1255437067
$20,159.71
in general payments reported to CMS, 2019-2025
71 companies · $2,720 in 2025
The $2,720 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,901 · 2020: $2,393 · 2021: $2,874 · 2022: $3,082 · 2023: $3,160 · 2024: $3,029 · 2025: $2,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,892 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,892.30 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,115.42 | 2019-2025 | |
| Ucb, INC. | $1,429.11 | 2019-2025 | Briviact, Rystiggo |
| Emd Serono, INC. | $1,324.63 | 2019-2025 | Mavenclad |
| Pfizer INC. | $1,156.65 | 2021-2025 | |
| Biogen, INC. | $1,039.19 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lilly USA, LLC | $978.72 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $952.79 | 2019-2025 | Rytary, Crexont |
| Grifols USA, LLC | $923.64 | 2019-2025 | Gamunex-C |
| Genentech USA, INC. | $837.29 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Genzyme Corporation | $694.01 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $606.78 | 2019-2023 | Austedo, Austedo Xr, Ajovy |
| Lundbeck LLC | $586.46 | 2019-2025 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $527.49 | 2019-2025 | Firdapse |
| Kyowa Kirin, INC. | $502.67 | 2020-2025 | Nourianz |
| Novartis Pharmaceuticals Corporation | $498.62 | 2019-2025 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.